...
lgnd-img

Ligand Pharmaceuticals Incorporated, Common Stock

LGND

NMQ

$114.09

-$0.32

(-0.28%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.16B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
45.9478
Volume info-icon
This is the total number of shares traded during the most recent trading day.
17.56K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.90
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$67.53 L
$129.9 H
$114.09

About Ligand Pharmaceuticals Incorporated, Common Stock

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameLGNDSectorS&P500
1-Week Return-4.94%-3.39%-3.47%
1-Month Return2.45%-3.25%-0.29%
3-Month Return10.35%-11.61%4.5%
6-Month Return42.05%-5.89%6.91%
1-Year Return65.33%2.65%23.79%
3-Year Return19.7%0.56%28.43%
5-Year Return70.11%34.63%83.64%
10-Year Return251.81%94.78%185.94%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue120.28M186.42M277.13M196.25M131.31M[{"date":"2019-12-31","value":43.4,"profit":true},{"date":"2020-12-31","value":67.27,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.81,"profit":true},{"date":"2023-12-31","value":47.38,"profit":true}]
Cost of Revenue11.35M30.42M62.18M52.83M35.05M[{"date":"2019-12-31","value":18.25,"profit":true},{"date":"2020-12-31","value":48.92,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.96,"profit":true},{"date":"2023-12-31","value":56.37,"profit":true}]
Gross Profit108.94M156.00M214.96M143.42M96.27M[{"date":"2019-12-31","value":50.68,"profit":true},{"date":"2020-12-31","value":72.57,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":66.72,"profit":true},{"date":"2023-12-31","value":44.78,"profit":true}]
Gross Margin90.57%83.68%77.56%73.08%73.31%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":92.4,"profit":true},{"date":"2021-12-31","value":85.64,"profit":true},{"date":"2022-12-31","value":80.69,"profit":true},{"date":"2023-12-31","value":80.95,"profit":true}]
Operating Expenses114.66M147.27M136.06M140.38M84.32M[{"date":"2019-12-31","value":77.85,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":92.39,"profit":true},{"date":"2022-12-31","value":95.32,"profit":true},{"date":"2023-12-31","value":57.26,"profit":true}]
Operating Income(5.72M)8.55M78.89M(25.50M)11.94M[{"date":"2019-12-31","value":-7.25,"profit":false},{"date":"2020-12-31","value":10.84,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-32.33,"profit":false},{"date":"2023-12-31","value":15.14,"profit":true}]
Total Non-Operating Income/Expense795.04M(55.73M)(50.39M)33.22M57.99M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-7.01,"profit":false},{"date":"2021-12-31","value":-6.34,"profit":false},{"date":"2022-12-31","value":4.18,"profit":true},{"date":"2023-12-31","value":7.29,"profit":true}]
Pre-Tax Income796.64M(10.54M)47.30M36.01M63.66M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-1.32,"profit":false},{"date":"2021-12-31","value":5.94,"profit":true},{"date":"2022-12-31","value":4.52,"profit":true},{"date":"2023-12-31","value":7.99,"profit":true}]
Income Taxes167.34M(7.55M)(10.29M)41.23M9.84M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-4.51,"profit":false},{"date":"2021-12-31","value":-6.15,"profit":false},{"date":"2022-12-31","value":24.64,"profit":true},{"date":"2023-12-31","value":5.88,"profit":true}]
Income After Taxes629.30M(2.98M)57.59M(5.22M)53.82M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-0.47,"profit":false},{"date":"2021-12-31","value":9.15,"profit":true},{"date":"2022-12-31","value":-0.83,"profit":false},{"date":"2023-12-31","value":8.55,"profit":true}]
Income From Continuous Operations629.30M(2.98M)57.59M(5.22M)21.10M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-0.47,"profit":false},{"date":"2021-12-31","value":9.15,"profit":true},{"date":"2022-12-31","value":-0.83,"profit":false},{"date":"2023-12-31","value":3.35,"profit":true}]
Income From Discontinued Operations(9.58M)(9.58M)(19.21M)(28.14M)-[{"date":"2019-12-31","value":-958300000,"profit":false},{"date":"2020-12-31","value":-958300000,"profit":false},{"date":"2021-12-31","value":-1921500000,"profit":false},{"date":"2022-12-31","value":-2814200000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Net Income629.30M(2.98M)57.14M(5.22M)52.15M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-0.47,"profit":false},{"date":"2021-12-31","value":9.08,"profit":true},{"date":"2022-12-31","value":-0.83,"profit":false},{"date":"2023-12-31","value":8.29,"profit":true}]
EPS (Diluted)3.044.556.424.286.10[{"date":"2019-12-31","value":47.35,"profit":true},{"date":"2020-12-31","value":70.87,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":66.67,"profit":true},{"date":"2023-12-31","value":95.02,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

LGND
Cash Ratio 8.87
Current Ratio 12.49
Quick Ratio 11.95

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

LGND
ROA (LTM) 1.30%
ROE (LTM) 6.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

LGND
Debt Ratio Lower is generally better. Negative is bad. 0.12
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.88

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

LGND
Trailing PE 45.95
Forward PE 18.55
P/S (TTM) 14.18
P/B 2.57
Price/FCF 97
EV/R 12.78
EV/Ebitda 20.35
PEG 1.53

FAQs

What is Ligand Pharmaceuticals Incorporated share price today?

Ligand Pharmaceuticals Incorporated (LGND) share price today is $114.09

Can Indians buy Ligand Pharmaceuticals Incorporated shares?

Yes, Indians can buy shares of Ligand Pharmaceuticals Incorporated (LGND) on Vested. To buy Ligand Pharmaceuticals Incorporated from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LGND stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Ligand Pharmaceuticals Incorporated be purchased?

Yes, you can purchase fractional shares of Ligand Pharmaceuticals Incorporated (LGND) via the Vested app. You can start investing in Ligand Pharmaceuticals Incorporated (LGND) with a minimum investment of $1.

How to invest in Ligand Pharmaceuticals Incorporated shares from India?

You can invest in shares of Ligand Pharmaceuticals Incorporated (LGND) via Vested in three simple steps:

  • Click on Sign Up or Invest in LGND stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Ligand Pharmaceuticals Incorporated shares
What is Ligand Pharmaceuticals Incorporated 52-week high and low stock price?

The 52-week high price of Ligand Pharmaceuticals Incorporated (LGND) is $129.9. The 52-week low price of Ligand Pharmaceuticals Incorporated (LGND) is $67.53.

What is Ligand Pharmaceuticals Incorporated price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Ligand Pharmaceuticals Incorporated (LGND) is 45.9478

What is Ligand Pharmaceuticals Incorporated price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Ligand Pharmaceuticals Incorporated (LGND) is 2.57

What is Ligand Pharmaceuticals Incorporated dividend yield?

The dividend yield of Ligand Pharmaceuticals Incorporated (LGND) is 0.00%

What is the Market Cap of Ligand Pharmaceuticals Incorporated?

The market capitalization of Ligand Pharmaceuticals Incorporated (LGND) is $2.16B

What is Ligand Pharmaceuticals Incorporated’s stock symbol?

The stock symbol (or ticker) of Ligand Pharmaceuticals Incorporated is LGND

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top